Integrative Genomic Profiling of Human Prostate Cancer

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

Abstract

Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in approximately 11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Biomarkers, Tumor / genetics*
  • Chromosomes, Human, Pair 3 / genetics
  • Comparative Genomic Hybridization
  • Gene Dosage
  • Gene Expression Profiling*
  • Genome, Human*
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Neoplasm Metastasis
  • Oligonucleotide Array Sequence Analysis
  • Oncogene Proteins, Fusion / genetics*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Signal Transduction
  • Transplantation, Heterologous
  • Tumor Cells, Cultured

Substances

  • Biomarkers, Tumor
  • Oncogene Proteins, Fusion
  • TMPRSS2-ERG fusion protein, human

Associated data

  • GEO/GSE21032